Explore

Rapid ReadRapid Read
Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics is a specialized field focused on the genomic analysis of tumors to guide cancer treatment decisions. This approach involves studying mutations in oncogenes and tumor suppressor genes, which are critical in the transformation of healthy cells into malignant ones. By understanding these genetic alterations, oncogenomics plays a pivotal role in personalized medicine, allowing for treatments to be tailored to an individual's unique genetic profile. This customization aims to reduce adverse reactions and improve overall healthcare outcomes. The open-access journal Oncotarget actively publishes research across all aspects of oncology, highlighting the ongoing advancements and importance of this field in medical research and practice. Personalized medicine, which includes oncogenomics, has been gaining momentum since the Human Genome Project's completion in 2003, enabling rapid advancements in genetic testing to identify disease-associated mutations.
Rapid ReadRapid Read
Boston University Researchers Develop Scalable Method for CAR-T Cancer Treatment

Boston University Researchers Develop Scalable Method for CAR-T Cancer Treatment

Researchers at the Center for Regenerative Medicine at Boston Medical Center and Boston University have developed a new, scalable method for generating CD4+ helper T cells from induced pluripotent stem cells (iPSCs). This breakthrough, published in Stem Cell Reports, addresses a significant challenge in the development of 'off-the-shelf' CAR-T therapies. Current CAR-T treatments involve collecting a patient's T cells, genetically modifying them to target cancer, and then reintroducing them, a process that is both expensive and time-consuming. The Boston team, led by Dr. Gustavo Mostoslavsky and doctoral student Julian Amirault, focused on manipulating the Notch molecular signaling pathway. They found that by removing Notch signaling during later stages of T cell maturation and simultaneously reducing anti-T cell receptor signaling, they could enable developing cells to survive and mature into functional CD4+ T cells at scale. This protocol is described as simple, straightforward, and potentially scalable f...
Rapid ReadRapid Read
BioNTech's Experimental Drug Gotistobart Shows Significant Survival Benefit in Aggressive Lung Cancer Trial

BioNTech's Experimental Drug Gotistobart Shows Significant Survival Benefit in Aggressive Lung Cancer Trial

BioNTech SE has announced that its experimental drug, gotistobart, nearly doubled the median survival rate for patients suffering from an aggressive form of lung cancer when compared to traditional chemotherapy. The updated results from a late-stage study indicate that patients treated with gotistobart lived for a median of 18.5 months, in contrast to 10 months for those receiving standard-of-care chemotherapy. This trial focused on individuals with metastatic squamous non-small cell lung cancer whose disease had progressed despite prior immunotherapy and chemotherapy treatments. Earlier data from the study had shown that gotistobart reduced the risk of death by 54%, though median overall survival had not been reached at that point. Rama Balaraman, a principal investigator in the trial and a medical oncologist, highlighted that current survival expectations with established therapies are typically less than a year, and chemotherapy has remained the standard for over a decade in this setting. BioNTech is co...
Rapid ReadRapid Read
BostonGene Expands AI-Powered Collaboration with Dana-Farber Cancer Institute for Breast Cancer Research

BostonGene Expands AI-Powered Collaboration with Dana-Farber Cancer Institute for Breast Cancer Research

BostonGene, a developer of AI models for tumor and immune biology, has expanded its scientific collaboration with the Dana-Farber Cancer Institute. This expanded partnership aims to deepen the understanding of the complex biological mechanisms driving BRCA1- and BRCA2-associated breast cancers. The collaboration will utilize BostonGene's foundation model of tumor and immune biology and multimodal AI analytics to place individual tumors within a broader biological context. This approach seeks to systematically discover mechanisms that differentiate disease subtypes, drive therapeutic response, and contribute to resistance. The research will focus on BRCA1/2-associated ER-positive breast cancer (BRCA ER+), TP53-mutant ER-positive breast cancer (TP53 ER+), and triple-negative breast cancer (TNBC).
Rapid ReadRapid Read
Precision Oncology Shifts Towards Integrating Multiple Biomarkers for Treatment Decisions

Precision Oncology Shifts Towards Integrating Multiple Biomarkers for Treatment Decisions

Precision oncology is increasingly moving beyond the reliance on single biomarkers to guide treatment decisions, instead emphasizing the integration of multiple genomic and molecular tests. Experts in a roundtable discussion highlighted that understanding cancer now requires combining diverse sources of molecular information to better comprehend tumor biology and personalize patient care. For instance, in colorectal cancer, the presence of both BRAF V600E mutation and MSI-high status provides two actionable biomarkers, often leading to immunotherapy as the initial treatment. In breast oncology, gene expression assays like Oncotype DX, which evaluate 21 genes, have been used for decades to determine which patients with early-stage ER-positive, HER2-negative breast cancer would benefit from chemotherapy, sparing millions from unnecessary treatments. The discussion also touched upon the complementary roles of protein-based and genomic testing for markers like microsatellite instability and HER2 status, indica...
Rapid ReadRapid Read
Memorial Sloan Kettering Cancer Center and OpenEvidence Partner to Integrate Precision Oncology Data into EHRs

Memorial Sloan Kettering Cancer Center and OpenEvidence Partner to Integrate Precision Oncology Data into EHRs

Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence have announced a partnership to advance precision oncology by integrating MSK's OncoKB™ knowledge base into OpenEvidence. This collaboration aims to provide clinicians nationwide with expert interpretation of cancer genomics directly within electronic health records (EHRs). OncoKB™, which is partially recognized by the U.S. Food and Drug Administration (FDA), offers evidence-based assertions on genetic alterations in cancer that can guide treatment decisions. The integration will allow OncoKB's curated content, including oncogenic effects, levels of evidence, and associated therapies, to be surfaced within OpenEvidence and Epic EHRs, alongside patient context. This initiative seeks to translate complex genomic reports into clear, evidence-based treatment paths, making MSK's expertise accessible to a broader network of cancer care providers across the U.S. More than half of U.S. hematologist-oncologists currently use OpenEvidence for complex onco...
TrendlineTrendline
Vyriad Initiates Phase 1 Clinical Trial for In Vivo CAR T Cell Therapy VV169 in Multiple Myeloma

Vyriad Initiates Phase 1 Clinical Trial for In Vivo CAR T Cell Therapy VV169 in Multiple Myeloma

Vyriad Initiates Phase 1 Clinical Trial for In Vivo CAR T Cell Therapy VV169 in Multiple Myeloma
Rapid ReadRapid Read
New Research Identifies Integrated Biomarkers for Rectal Cancer Treatment Response

New Research Identifies Integrated Biomarkers for Rectal Cancer Treatment Response

A recent study published in Frontiers in Genetics has identified integrated biomarkers that link systemic inflammation and nutrition status to the tumor immune microenvironment, providing insights into neoadjuvant response in locally advanced rectal cancer (LARC). The research focused on the inflammation-nutrition prognostic score (INPS), calculated as the neutrophil-to-lymphocyte ratio (NLR) divided by the prognostic nutritional index (PNI). This score integrates systemic inflammatory burden and nutritional-immunological reserve. The study retrospectively analyzed 312 LARC patients who received standard neoadjuvant chemoradiotherapy, with or without concurrent PD-1/PD-L1 blockade, followed by total mesorectal excision. The findings indicate that a low INPS (<0.058) was significantly associated with a higher objective response rate (61.3% vs. 29.4%) and pathological complete response (38.7% vs. 11.8%). The INPS demonstrated a strong predictive capability for treatment response, outperforming other individu...
Rapid ReadRapid Read
Cullinan and Taiho Plan FDA Filing for Lung Cancer Pill Zipalertinib Despite Patient Deaths

Cullinan and Taiho Plan FDA Filing for Lung Cancer Pill Zipalertinib Despite Patient Deaths

Taiho Oncology and Cullinan Therapeutics are moving forward with plans to file for FDA approval of their oral drug candidate, zipalertinib, for non-small cell lung cancer (NSCLC), despite three patient deaths reported during a late-stage study. The Phase 3 REZILIENT3 trial demonstrated that zipalertinib, when combined with chemotherapy, significantly improved progression-free survival (PFS) in patients with first-line advanced non-squamous NSCLC harboring exon 20 mutations to the EGFR gene. Patients receiving the zipalertinib regimen experienced a 50% reduction in the risk of death or disease progression, with a median PFS of 14.5 months compared to 8.5 months in the control group. While adverse events of grade 3 or higher were more frequent in the zipalertinib arm (87% vs. 54.4%), analysts believe the robust efficacy and potential mitigation strategies will outweigh the safety concerns.
Rapid ReadRapid Read
NRG Oncology Advocate Calls for Enhanced Biomarker Testing and Reduced Treatment Toxicity in Gynecologic Cancer Care

NRG Oncology Advocate Calls for Enhanced Biomarker Testing and Reduced Treatment Toxicity in Gynecologic Cancer Care

Rachel Miller-Garcia, a patient advocate and member of the NRG Oncology Patient Advocate Committee, is urging clinicians to prioritize biomarker testing and circulating tumor DNA (ctDNA) testing as standard of care in gynecologic cancer treatment. She emphasizes that ctDNA testing can determine treatment efficacy or progression months earlier than traditional scanning, potentially reducing unnecessary radiation exposure and debilitating side effects. Miller-Garcia also advocates for addressing treatment toxicity and side effects more proactively in clinical trials, suggesting that lower doses of therapies might be equally effective and more manageable for patients. She highlights significant advancements in treatment, including PARP inhibitors and Antibody Drug Conjugates (ADCs), and the progress in precision medicine through personalized, targeted therapies based on biomarkers and genomic testing. Despite these advances, she notes that side effects from targeted therapies are often underreported in real-w...
TrendlineTrendline
Biotechnology ETFs Offer Investment Opportunities in U.S. Market

Biotechnology ETFs Offer Investment Opportunities in U.S. Market

Biotechnology ETFs Offer Investment Opportunities in U.S. Market
TrendlineTrendline
TwoStep Therapeutics Secures $62.5 Million Series A Funding and FDA Clearance for Cancer Drug

TwoStep Therapeutics Secures $62.5 Million Series A Funding and FDA Clearance for Cancer Drug

TwoStep Therapeutics Secures $62.5 Million Series A Funding and FDA Clearance for Cancer Drug